AB Science SA
PAR:AB

Watchlist Manager
AB Science SA Logo
AB Science SA
PAR:AB
Watchlist
Price: 1.364 EUR -1.16% Market Closed
Market Cap: 90.3m EUR

Net Margin

-831.5%
Current
Improving
by 318%
vs 3-y average of -1 149.4%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-831.5%
=
Net Income
€-8.5m
/
Revenue
€1m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-831.5%
=
Net Income
€-8.5m
/
Revenue
€1m

Peer Comparison

Country Company Market Cap Net
Margin
FR
AB Science SA
PAR:AB
91.3m EUR
Loading...
US
Eli Lilly and Co
NYSE:LLY
982.2B USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
524.3B USD
Loading...
CH
Roche Holding AG
SIX:ROG
273.4B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
208.3B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
270.2B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.7B USD
Loading...
No Stocks Found

Market Distribution

Lower than 95% of companies in France
Percentile
5th
Based on 2 398 companies
5th percentile
-831.5%
Low
-147 400% — -2.2%
Typical Range
-2.2% — 7.1%
High
7.1% — 14 243.8%
Distribution Statistics
France
Min -147 400%
30th Percentile -2.2%
Median 2.6%
70th Percentile 7.1%
Max 14 243.8%

AB Science SA
Glance View

Market Cap
90.3m EUR
Industry
Pharmaceuticals

AB Science SA engages in the research, development, and sales of protein kinase inhibitor drugs. The company is headquartered in Paris, Ile-De-France and currently employs 96 full-time employees. The company went IPO on 2010-04-21. The company is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine. The main focus of the Company is the development of tyrosine kinase inhibitors, for instance Masitinib which is a tyrosine kinase inhibitor used as a veterinary medicine in the treatment of canine mast cell tumors. The firm is present in the United States and Europe. As of December 31, 2013, the Company operated though a subsidiary, AB Science USA LCC, based in the United States.

AB Intrinsic Value
0.088 EUR
Overvaluation 94%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-831.5%
=
Net Income
€-8.5m
/
Revenue
€1m
What is AB Science SA's current Net Margin?

The current Net Margin for AB Science SA is -831.5%, which is above its 3-year median of -1 149.4%.

How has Net Margin changed over time?

Over the last 3 years, AB Science SA’s Net Margin has increased from -1 195.3% to -831.5%. During this period, it reached a low of -2 119.7% on Jun 30, 2023 and a high of -558.1% on Jun 30, 2024.

Back to Top